Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Andrew Funderburk - Senior Vice President, Investor Relations and Strategic Finance Markus Warmuth - Chief Executive Officer Filip Janku - Chief Medical Officer Sharon Townson - Chief Scientific Officer Phil Nickson - Chief Business and Legal Officer Conference Call Participants Kelly Shi - Jefferies Edward Tenthoff - Piper Sandler Mark Fromm - TD Cowen Robert Driscoll - Wedbush Michael Schmidt - Guggenheim Eric Joseph - JPMorgan Operator Greetings, and welcome to Monte Rosa Therapeutics Conference Call to discuss the company's pipeline updates and clinical results. At this time, all participants are in a listen-only mode.
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates
Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.58 per share a year ago.
Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 64.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 100.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.70 per share a year ago.
Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice
Does Monte Rosa Therapeutics (GLUE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Monte Rosa Therapeutics (GLUE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.71 per share a year ago.
